B-cell depletion attenuates white and gray matter pathology in marmoset experimental autoimmune encephalomyelitis

Journal of Neuropathology and Experimental Neurology

Volumn 70, Issue 11, 2011, Pages 992-1005

  Kap, Yolanda S ^a,b   Bauer, Jan ^c   Driel, Nikki Van ^a   Bleeker, Wim K ^d   Parren, Paul W H I ^d   Kooi, Evert Jan ^e,f   Geurts, Jeroen J G ^e,f   Laman, Jon D ^b   Craigen, Jenny L ^g   Blezer, Erwin ^h   'T Hart, Bert A ^a,b,i  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d GENMAB   (Netherlands)

^e Erasmus MC Cancer Institute   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g GLAXOSMITHKLINE   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

B cell; Callithrix jacchus; Demyelination; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Ofatumumab; Rituximab

Indexed keywords

CD20 ANTIBODY; HUMAN MONOCLONAL ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BRAIN; CALLITRICHINAE; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATION; GRAY MATTER; IMMUNIZATION; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE DEPLETION; MALE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; PRIORITY JOURNAL; SPINAL CORD; WHITE MATTER;

ANIMALS; ANTIBODIES; ANTIGENS, CD20; ANTIGENS, CD9; B-LYMPHOCYTES; BRAIN; CALGRANULIN B; CALLITHRIX; COMPLEMENT C9; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FREUND'S ADJUVANT; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MAGNETIC RESONANCE IMAGING; MYELIN PROTEINS; MYELIN PROTEOLIPID PROTEIN; NERVE FIBERS, MYELINATED; NEUROFILAMENT PROTEINS; STATISTICS, NONPARAMETRIC;

EID: 80054896628     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318234d421     Document Type: Article

References (43)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
2. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008;7:841-51
3. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747 (Pubitemid 40563183)
4. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88 (Pubitemid 351240747)
5. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsingremitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400 (Pubitemid 351499869)
6. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cellYmediated disease in MS? Ann Neurol 2010;67:452-61
7. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized doubleblind placebo-controlled multicenter trial. Ann Neurol 2009;66:460-71
8. Hart BA, Massacesi L. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J Neuropathol Exp Neurol 2009;68:341-55
9. Kap YS, Laman JD, Hart BA. Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development. J Neuroimmune Pharmacol 2010;5:220-30
10. Hart BA, Laman JD, Bauer J, et al. Modelling of multiple sclerosis: Lessons learned in a non-human primate. Lancet Neurol 2004;3:588-97 (Pubitemid 39232075)
11. Pomeroy IM, Matthews PM, Frank JA, et al. Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 2005;128:2713-21 (Pubitemid 41552954)
12. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800 (Pubitemid 39202289)
13. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71 (Pubitemid 43939148)
14. Kap YS, van Driel N, Blezer E, et al. Late B cell depletion with a human anti-human CD20 IgG1kappa monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets. J Immunol 2010;185:3990-4003
15. Kap YS, Smith P, Jagessar SA, et al. Fast progression of recombinant human myelin/oligodendrocyte glycoprotein (MOG)Yinduced experimental autoimmune encephalomyelitis in marmosets is associated with the activation of MOG34-56-specific cytotoxic T cells. J Immunol 2008; 180:1326-37
16. Kerlero de Rosbo N, Hoffman M, Mendel I, et al. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol 1997;27:3059-69 (Pubitemid 27478380)
17. Hart BA, Hintzen RQ, Laman JD. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis. Neurodegener Dis 2008;5:38-52 (Pubitemid 350261815)
18. Bleeker WK, Munk ME, Mackus WJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human antiYCD20 antibody. Br J Haematol 2008;140:303-12
19. Blezer EL, Bauer J, Brok HP, et al. Quantitative MRI-pathology correlations of brain white matter lesions developing in a nonYhuman primate model of multiple sclerosis. NMR Biomed 2007;20:90-103 (Pubitemid 46470931)
20. Hart BA, Bauer J, Muller HJ, et al. Histopathological characterization of magnetic resonance imagingYdetectable brain white matter lesions in a primate model of multiple sclerosis: A correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am J Pathol 1998;153:649-63 (Pubitemid 28373674)
21. Laman JD, van Meurs M, Schellekens MM, et al. Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). J Neuroimmunol 1998;86:30-45 (Pubitemid 28293947)
22. Kooi EJ, Geurts JJ, van Horssen J, et al. Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. J Neuropathol Exp Neurol 2009;68:1021-28
23. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85 (Pubitemid 28065253)
24. von Büdingen HC, Tanuma N, Villoslada P, et al. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J Clin Immunol 2001;21:155-70 (Pubitemid 32434302)
25. Matsushita T, Yanaba K, Bouaziz JD, et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008;118:3420-30
26. Kutzelnigg A, Lassmann H. Cortical lesions and brain atrophy in MS. J Neurol Sci 2005;233:55-59 (Pubitemid 40804816)
27. Bo L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323-31 (Pubitemid 36958014)
28. Brink BP, Veerhuis R, Breij EC, et al. The pathology of multiple sclerosis is location-dependent: No significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005;64:147-55 (Pubitemid 40349313)
29. van Horssen J, Brink BP, de Vries HE, et al. The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol 2007;66: 321-28 (Pubitemid 46559025)
30. Bo L, Vedeler CA, Nyland HI, et al. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003;62:723-32 (Pubitemid 36870458)
31. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-104 (Pubitemid 47355604)
32. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17 (Pubitemid 30390191)
33. Genain CP, Nguyen MH, Letvin NL, et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 1995; 96:2966-74
34. McFarland HI, Lobito AA, Johnson MM, et al. Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J Immunol 1999;162:2384-90 (Pubitemid 29288866)
35. Jagessar SA, Kap YS, Heijmans N, et al. Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete Freund adjuvant. J Neuropathol Exp Neurol 2010;69:372-85
36. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010;68: 369-83
37. Monson NL, Cravens P, Hussain R, et al. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One 2011;6:e17103
38. Tedder TF, Klejman G, Disteche CM, et al. Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19. J Immunol 1988;141:4388-94 (Pubitemid 19018233)
39. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092-99 (Pubitemid 46717389)
40. Lund FE, Randall TD. Effector and regulatory B cells: Modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010;10:236-47
41. Matsushita T, Horikawa M, Iwata Y, et al. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 2010;185:2240-52
42. Bouaziz JD, Yanaba K, Venturi GM, et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007;104:20878-83
43. Hamel K, Doodes P, Cao Y, et al. Suppression of proteoglycan-induced arthritis by antiYCD20 B cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J Immunol 2008;180: 4994-5003